Nuvation Bio and Eisai Enter into Exclusive Licensing Agreement for Taletrectinib in Europe and Additional Countries Outside U.S., China and Japan
NUVBNEW YORK & TOKYO--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB, Corporate Headquarters: New York, NY, CEO: David Hung, M.D., “Nuvation Bio”), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, and Eisai Co., Ltd (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”), a human-centered global leading research-based pharmaceutical company working in the neurology and oncology therapeutic areas, today announced an exclusive license and collaboration agree
Nuvation Bio to Participate in Upcoming Investor Conferences
NUVBNEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that David Hung, M.D., Founder, President, and Chief Executive Officer of Nuvation Bio, and Philippe Sauvage, Chief Financial Officer of Nuvation Bio, will participate in three upcoming investor conferences, including fireside chats at two conferences: Cantor Global Healthcare Conference 2025 on Thursday, September 4, 2025,
Nuvation Bio Reports Second Quarter 2025 Financial Results and Provides Business Update
NUVBNEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a global oncology company tackling some of the toughest challenges in cancer treatment, today reported financial results for the second quarter ended June 30, 2025, and provided a business update. “With FDA approval of IBTROZI, we’re proud of our swift evolution into a commercial‐stage company executing across functions to deliver a differentiated therapy to 70 patients in just seven weeks,” said David Hung, M.D., Founder, President, an
Nuvation Bio To Present New Data on IBTROZI™ (taletrectinib) in Advanced ROS1-Positive Non-Small Cell Lung Cancer at WCLC and ESMO Annual Congresses
NUVBNEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that new data will be presented at the IASLC 2025 World Conference on Lung Cancer (WCLC) taking place September 6–9, 2025 in Barcelona, Spain, and the European Society of Medical Oncology Congress Meeting (ESMO) October 17–21, 2025 in Berlin, Germany. These data include new results from the pivotal Phase 2 TRUST-I and TRUST
Wedbush Maintains Outperform on Nuvation Bio, Maintains $5 Price Target
NUVBNuvation Bio's Ibtrozi For ROS1-Positive Lung Cancer Wins FDA Approval
NUVBFDA approves Ibtrozi for ROS1+ non-small cell lung cancer based on data from over 300 patients in two pivotal trials showing high response rates.
Nuvation Bio Shares Halted On Circuit Breaker To The Downside, Stock Now Down -4.80%
NUVBU.S. Food and Drug Administration Approves Nuvation Bio’s IBTROZI™ (taletrectinib), a Next-Generation Oral Treatment for Advanced ROS1-Positive Non-Small Cell Lung Cancer
NUVBNEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that the U.S. Food and Drug Administration (FDA) has approved IBTROZI™ (taletrectinib) for the treatment of adult patients with locally advanced or metastatic ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC). IBTROZI is a highly selective, next-generation oral ROS1 tyrosine kinase inhibitor (TKI) designed to address
FDA Approves Taletrectinib For ROS1-Positive Non-Small Cell Lung Cancer
NUVBJMP Securities Reiterates Market Outperform on Nuvation Bio, Maintains $6 Price Target
NUVBNuvation Bio To Present Addl Results From TRUST-I And TRUST-II, Pivotal Phase 2 Clinical Studies On Efficacy And Safety Of Taletrectinib For Advanced ROS1+ NSCLC Treatment At ASCO 2025 Annual Meeting
NUVBWedbush Reiterates Outperform on Nuvation Bio, Maintains $5 Price Target
NUVBNuvation Bio Q1 EPS $(0.16), Inline, Sales $3.08M Beat $416.67K Estimate
NUVBJMP Securities Initiates Coverage On Nuvation Bio with Market Outperform Rating, Announces Price Target of $6
NUVBJones Trading Initiates Coverage On Nuvation Bio with Buy Rating, Announces Price Target of $10
NUVBHC Wainwright & Co. Maintains Buy on Nuvation Bio, Lowers Price Target to $10
NUVBNuvation Bio Q4 2024 GAAP EPS $(0.15) Misses $(0.14) Estimate
NUVBNuvation Bio Enters Supply Agreement With Asymchem For Taletrectinib; 5-Year Initial Term With Automatic 3-Year Renewals
NUVBNuvation Bio Announces Non-Dilutive Financings Up To $250M With Sagard Healthcare Partners Including Royalty Interest Financing Of $150M And Senior Term Loan Of $100M
NUVBNuvation Bio shares are trading higher after the company announced the FDA accepted the New Drug Application for taletrectinib for the treatment of advanced ROS1+ NSCLC.
NUVBNuvation Bio Announces The U.S. FDA Accepts For Priority Review Nuvation Bio's New Drug Application For Taletrectinib For The Treatment Of Advanced ROS1-Positive Non-Small Cell Lung Cancer
NUVBHC Wainwright & Co. Reiterates Buy on Nuvation Bio, Maintains $8 Price Target
NUVBHC Wainwright & Co. Initiates Coverage On Nuvation Bio with Buy Rating, Announces Price Target of $14
NUVB